Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2022

View Archived Issues

Teixobactin attenuates anthrax infection in a rabbit model

Loss-of-function mutations in ZFHX3 cause intellectual disability

Astrocyte-specific IL-2 delivery shows neuroprotective effect in four neuroinflammation models

Beijing Increase Innovation Drug Research divulges SGLT2 inhibitors

Roche discloses new HBV antivirals

Qilu Regor Therapeutics presents new STING antagonists

Fochon Pharmaceuticals identifies new BTK inhibitors

DA-1726 shows efficacy in diet-induced NASH mouse model

Chinese researchers disclose cardiac myosin inhibitors

Novel neurodevelopmental disorder associated with germline variants in FBXW7

Omadacycline, a promising treatment approach for chlamydial infections

NXP-900 shows tumor growth inhibition and survival benefit in mouse model of group 4 medulloblastoma

Alpha Cognition announces discovery of GEM combinations ALPHA-0702 and ALPHA-0802

Discovery of novel cathepsin C inhibitor with anti-inflammatory activity in vivo

Evotec and Janssen Pharmaceutica establish drug discovery collaboration

Hamlet and Neurochase partner to develop novel technology to deliver Alpha-1H for CNS tumors

EHA 2022 presentations describe sickle cell disease headway and headwinds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...